American Journal of Obstetrics & Gynecology
Volume 199, Issue 6, Supplement B , Pages S296-S309 , December 2008

The clinical content of preconception care: infectious diseases in preconception care

  • Dean V. Coonrod, MD, MPH

      Affiliations

    • Department of Obstetrics and Gynecology, Maricopa Medical Center, Phoenix, AZ
    • Corresponding Author InformationReprints: Dean V Coonrod, MD, MPH, Chair, Department of Obstetrics and Gynecology, Maricopa Medical Center, OBGYN Dept, 2nd Floor Admin, 2601 E Roosevelt St, Phoenix, AZ 85008
    • ,
  • Brian W. Jack, MD

      Affiliations

    • Department of Family Medicine, Boston University Medical Center, Boston MA
    • ,
  • Phillip G. Stubblefield, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Boston University Medical Center, Boston MA
    • ,
  • Lisa M. Hollier, MD, MPH

      Affiliations

    • Department of Obstetrics, Gynecology and Reproductive Sciences, University of Texas-Houston, Houston, TX
    • ,
  • Kim A. Boggess, MD

      Affiliations

    • Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC
    • ,
  • Robert Cefalo, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC
    • ,
  • Shanna N. Cox, MSPH

      Affiliations

    • Centers for Disease Control, Division of Reproductive Health/NCCDPHP, Atlanta, GA
    • ,
  • Anne L. Dunlop, MD, MPH

      Affiliations

    • Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, GA
    • ,
  • Kam D. Hunter, MD, PhD

      Affiliations

    • Department of Family and Community Medicine, Maricopa Medical Center, Phoenix, AZ
    • ,
  • Mona R. Prasad, DO, MPH

      Affiliations

    • Department of Obstetrics & Gynecology, The Ohio State University, Columbus, OH
    • ,
  • Michael C. Lu, MD, MS, MPH

      Affiliations

    • Departments of Obstetrics & Gynecology and Community Health Sciences, UCLA Schools of Medicine & Public Health, Los Angeles CA
    • ,
  • Jeanne A. Conry, MD, PhD

      Affiliations

    • Department of Women's Health, Kaiser Permanente, Roseville, CA
    • ,
  • Ronald S. Gibbs, MD

      Affiliations

    • Department of Obstetrics and Gynecology, University of Colorado Health Sciences Center. Denver, CO
    • ,
  • Vijaya K. Hogan, DrPH

      Affiliations

    • Department of Maternal and Child Health, School of Public Health, University of North Carolina, Chapel Hill, NC

Received 13 June 2008 ,Accepted 29 August 2008.

References 

  1. Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Rep. 2001;50:1–58
  2. Revised guidelines for HIV counseling, testing, and referral and revised recommendations for HIV screening of pregnant women. MMWR Recomm Rep. 2001;(RR-19):59–85
  3. Centers for Disease Control and Prevention (CDC). HIV testing among pregnant women: United States and Canada, 1998-2001. MMWR Morb Mortal Wkly Rep. 2002;51:1013–1016
  4. Kilby JM. Human immunodeficiency disease: ACP PIER & AHFS DI essentials. Philadelphia: American College of Physicians; 2008;
  5. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 study group. N Engl J Med. 1994;331:1173–1180
  6. Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis. 2001;183:539–545
  7. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Rockville (MD): US Department of Health and Human Services; 2006;
  8. American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG committee opinion no.: 304, November 2004: prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. Obstet Gynecol. 2004;104:1119–1124
  9. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1–17
  10. Chou R, Huffman L. Screening for human immunodeficiency virus: focused update of a 2005 systematic evidence review for the U.S. preventive services task force. Prepared for the Agency for Healthcare Research and Quality by the Oregon Evidence-based Practice Center at the Oregon Health and Science University, Portland, Oregon, under Contract No. 290-02-0024, Task Order Number 1. AHRQ Publication No. 07-0597-EF-1. Rockville, MD: Agency for Healthcare Research and Quality. April 2007.
  11. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep. 2002;51:1–38
  12. Hawkins D, Blott M, Clayden P, et al. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV. HIV Med. 2005;6(suppl):107–148
  13. Reinus JF, Leikin EL, Alter HJ, et al. Failure to detect vertical transmission of hepatitis C virus. Ann Intern Med. 1992;117:881–886
  14. Moriya T, Sasaki F, Mizui M, et al. Transmission of hepatitis C virus from mothers to infants: its frequency and risk factors revisited. Biomed Pharmacother. 1995;49:59–64
  15. Bohman VR, Stettler RW, Little BB, Wendel GD, Sutor LJ, Cunningham FG. Seroprevalence and risk factors for hepatitis C virus antibody in pregnant women. Obstet Gynecol. 1992;80:609–613
  16. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171
  17. Zanetti AR, Tanzi E, Newell ML. Mother-to-infant transmission of hepatitis C virus. J Hepatol. 1999;31(suppl):96–100
  18. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005;54:1–47
  19. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60:555–564
  20. Jerant AF, Bannon M, Rittenhouse S. Identification and management of tuberculosis. Am Fam Physician. 2000;61:2667–26782681-2
  21. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000;49:1–51
  22. Wilson CB, Remington JS. What can be done to prevent congenital toxoplasmosis?. Am J Obstet Gynecol. 1980;138:357–363
  23. Lopez A, Dietz VJ, Wilson M, Navin TR, Jones JL. Preventing congenital toxoplasmosis. MMWR Recomm Rep. 2000;49:59–68
  24. Krick JA, Remington JS. Toxoplasmosis in the adult: an overview. N Engl J Med. 1978;298:550–553
  25. Fuccillo DA, Madden DL, Tzan N, Sever JL. Difficulties associated with serological diagnosis of Toxoplasma gondii infections. Diagn Clin Immunol. 1987;5:8–13
  26. American College of Obstetricians and Gynecologists. ACOG practice bulletin: perinatal viral and parasitic infections. Washington (DC): The College; 2000;
  27. Preventing congenital toxoplasmosis. MMWR Morb Mortal Weekly Rep. 2000;49:57–75
  28. Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy (Incidence, transmission to fetus, and clinical outcome). JAMA. 1986;256:1904–1908
  29. Nigro G, Adler SP, La Torre R, Best AM. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005;353:1350–1362
  30. Onorato IM, Morens DM, Martone WJ, Stansfield SK. Epidemiology of cytomegaloviral infections: recommendations for prevention and control. Rev Infect Dis. 1985;7:479–497
  31. Duff P. A thoughtful algorithm for the accurate diagnosis of primary CMV infection in pregnancy. Am J Obstet Gynecol. 2007;196:196–197
  32. Centers For Disease Control and Prevention. Cytomegalovirus (CMV): pregnancy. http://www.cdc.gov/cmv/pregnancy.htmAccessed on March 23, 2008
  33. Siegman-Igra Y, Levin R, Weinberger M, et al. Listeria monocytogenes infection in Israel and review of cases worldwide. Emerg Infect Dis. 2002;8:305–310
  34. Varma JK, Samuel MC, Marcus R, et al. Listeria monocytogenes infection from foods prepared in a commercial establishment: a case-control study of potential sources of sporadic illness in the United States. Clin Infect Dis. 2007;44:521–528
  35. Gellin BG, Broome CV. Listeriosis. JAMA. 1989;261:1313–1320
  36. Craig S, Permezel M, Doyle L, Mildenhall L, Garland S. Perinatal infection with Listeria monocytogenes. Aust N Z J Obstet Gynaecol. 1996;36:286–290
  37. Ross DS, Jones JL, Lynch MF. Toxoplasmosis, cytomegalovirus, listeriosis, and preconception care. Matern Child Health J. 2006;10:S187–S191
  38. Outbreak of listeriosis associated with homemade Mexican-style cheese: North Carolina, October 2000-January 2001. MMWR Morb Mortal Wkly Rep. 2001;50:560–562
  39. American College of Obstetricians and Gynecologists. ACOG patient education pamphlet AP001: nutrition during pregnancy. Washington (DC): The College; 2007;
  40. Rodis JF, Hovick TJ, Quinn DL, Rosengren SS, Tattersall P. Human parvovirus infection in pregnancy. Obstet Gynecol. 1988;72:733–738
  41. Rodis JF, Quinn DL, Gary GW, et al. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. Am J Obstet Gynecol. 1990;163:1168–1171
  42. Enders M, Weidner A, Zoellner I, Searle K, Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn. 2004;24:513–518
  43. Schild RL, Bald R, Plath H, Eis-Hubinger AM, Enders G, Hansmann M. Intrauterine management of fetal parvovirus B19 infection. Ultrasound Obstet Gynecol. 1999;13:161–166
  44. Rodis JF, Borgida AF, Wilson M, et al. Management of parvovirus infection in pregnancy and outcomes of hydrops: a survey of members of the Society of Perinatal Obstetricians. Am J Obstet Gynecol. 1998;179:985–988
  45. Levy R, Weissman A, Blomberg G, Hagay ZJ. Infection by parvovirus B 19 during pregnancy: a review. Obstet Gynecol Surv. 1997;52:254–259
  46. Rodis JF, Rodner C, Hansen AA, Borgida AF, Deoliveira I, Shulman Rosengren S. Long-term outcome of children following maternal human parvovirus B19 infection. Obstet Gynecol. 1998;91:125–128
  47. Nagel HT, de Haan TR, Vandenbussche FP, Oepkes D, Walther FJ. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection. Obstet Gynecol. 2007;109:42–47
  48. Okoko BJ, Enwere G, Ota MO. The epidemiology and consequences of maternal malaria: a review of immunological basis. Acta Trop. 2003;87:193–205
  49. Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104
  50. Centers for Disease Control and Prevention. Malaria during pregnancy. http://www.cdc.gov/malaria/pregnancy.htmAccessed March 23, 2008
  51. Skarbinski J, James EM, Causer LM, et al. Malaria surveillance: United States, 2004. MMWR Surveill Summ. 2006;55:23–37
  52. Centers for Disease Control and Prevention. Malaria: diagnosis–microscopy. http://www.cdc.gov/malaria/diagnosis_treatment/microscopy.htmAccessed March 23, 2008
  53. Centers for Disease Control and Prevention. Malaria: Diagnosis–rapid diagnostic test. http://www.cdc.gov/malaria/diagnosis_treatment/diagnosis_rdt.htmAccessed March 23, 2008
  54. Centers for Disease Control and Prevention. Guidelines for treatment of malaria in the United States. http://www.cdc.gov/malaria/pdf/treatmenttable.pdfAccessed March 23, 2008
  55. Centers for Disease Control and Prevention. Malaria treatment guidelines. http://www.cdc.gov/malaria/pdf/clinicalguidance.pdfAccessed March 23, 2008
  56. Menendez C, D'Alessandro U, ter Kuile FO. Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis. 2007;7:126–135
  57. Koren G, Matsui D, Bailey B. DEET-based insect repellents: safety implications for children and pregnant and lactating women. CMAJ. 2003;169:209–212
  58. McGready R, Hamilton KA, Simpson JA, et al. Safety of the insect repellent N,N-diethyl-M-toluamide (DEET) in pregnancy. Am J Trop Med Hyg. 2001;65:285–289
  59. Gamble C, Ekwaru PJ, Garner P, ter Kuile FO. Insecticide-treated nets for the prevention of malaria in pregnancy: a systematic review of randomized controlled trials. PLoS Med. 2007;4:e107
  60. Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis. 2007;7:136–144
  61. Centers for Disease Control and Prevention. Preconception planning, pregnancy and travel. http://www2.ncid.cdc.gov/travel/yb/utils/ybGet.asp?section=special&obj=pregnant.htmAccessed March 23, 2008
  62. Greenwood B, Alonso P, ter Kuile FO, Hill J, Steketee RW. Malaria in pregnancy: priorities for research. Lancet Infect Dis. 2007;7:169–174
  63. Centers for Disease Control and Prevention. Travelers' health: malaria. http://wwwn.cdc.gov/travel/contentMalariaDrugsHC.aspxAccessed March 24, 2008
  64. Centers for Disease Control and Prevention. Travelers' health—information for health care providers: preventing malaria in the pregnant woman. http://wwwn.cdc.gov/travel/contentMalariaPregnantHC.aspxAccessed March 24, 2008
  65. Centers for Disease Control and Prevention: Division of STD Prevention. STD surveillance 2006. http://www.cdc.gov/std/stats/Tables/Table1.htmAccessed March 24, 2008
  66. US Preventive Services Task Force. Screening for gonorrhea: recommendation statement. Ann Fam Med. 2005;3:263–267
  67. Johnson RE, Newhall WJ, Papp JR, et al. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections: 2002. MMWR Recomm Rep. 2002;51:1–38
  68. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55:38–49
  69. Updated recommended treatment regimens for gonococcal infections and associated conditions: United States, April 2007. MMWR Morb MortalWeekly Rep. 2007;56:332–336
  70. US Preventive Services Task Force. Screening for gonorrhea. http://www.ahrq.gov/clinic/uspstf/uspsgono.htmAccessed March 24, 2008
  71. US Preventive Services Task Force. Screening for chlamydial infection: recommendations and rationale. Am J Prev Med. 2001;20:90–94
  72. US Preventive Services Task Force. Screening for chlamydial infection. http://www.ahrq.gov/clinic/uspstf/uspschlm.htmAccessed March 24, 2008
  73. Nelson HD, Glass N, Huffman L, Villemyer K, Hamilton A. Screening for syphilis: a brief update for the US Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality; 2004;
  74. US Preventive Services Task Force. Screening for syphilis. Washington (DC): Office of Disease Prevention and Health Promotion; 2004;
  75. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis. 2004;190:1374–1381
  76. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350:11–20
  77. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296:964–973
  78. American College of Obstetricians and Gynecologists. ACOG practice bulletin. No.: 82: management of herpes in pregnancy. Washington (DC): The College; 2000;
  79. US Preventive Services Task Force. Screening for asymptomatic bacteriuria. http://www.ahrq.gov/clinic/uspstf/uspsbact.htmAccessed October 20, 2008
  80. Offenbacher S, Lieff S, Boggess KA, et al. Maternal periodontitis and prematurity: part I: obstetric outcome of prematurity and growth restriction. Ann Periodontol. 2001;6:164–174
  81. Jeffcoat MK, Hauth JC, Geurs NC, et al. Periodontal disease and preterm birth: results of a pilot intervention study. J Periodontol. 2003;74:1214–1218
  82. Boggess KA, Lieff S, Murtha AP, Moss K, Beck J, Offenbacher S. Maternal periodontal disease is associated with an increased risk for preeclampsia. Obstet Gynecol. 2003;101:227–231
  83. Lopez NJ, Smith PC, Gutierrez J. Periodontal therapy may reduce the risk of preterm low birth weight in women with periodontal disease: a randomized controlled trial. J Periodontol. 2002;73:911–924
  84. Michalowicz BS, Hodges JS, DiAngelis AJ, et al. Treatment of periodontal disease and the risk of preterm birth. N Engl J Med. 2006;355:1885–1894
  85. American Academy of Periodontology Task Force on Periodontal Treatment of Pregnant Women. American Academy of Periodontology statement regarding periodontal management of the pregnant patient. J Periodontol. 2004;75:495
  86. Ismail AI, Lewis DW, Dingle JL. Prevention of periodontal disease. In: Canadian Guide to Clinical Preventive Health Care. Ottawa: Health Canada; 1994;
  87. Hillier SL, Krohn MA, Rabe LK, Klebanoff SJ, Eschenbach DA. The normal vaginal flora, H2O2-producing lactobacilli, and bacterial vaginosis in pregnant women. Clin Infect Dis. 1993;16(suppl):S273–S281
  88. Lamont RF, Fisk NM. The role of infection in the pathogenesis of preterm labour. vol 10 In:  Studd JWW editors. Progress in obstetrics and gynaecology. London: Churchill Livingstone; 1993;
  89. Koumans E, Markowitz LE, Hogan V CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis. 2002;35(suppl):S152–S172
  90. McGregor JA, French JI, Richter R, et al. Antenatal microbiologic and maternal risk factors associated with prematurity. Am J Obstet Gynecol. 1990;163:1465–1473
  91. Kurki T, Sivonen A, Renkonen OV, Savia E, Ylikorkala O. Bacterial vaginosis in early pregnancy and pregnancy outcome. Obstet Gynecol. 1992;80:173–177
  92. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant: the Vaginal Infections and Prematurity Study group. N Engl J Med. 1995;333:1737–1742
  93. Hay PE, Lamont RF, Taylor-Robinson D, Morgan DJ, Ison C, Pearson J. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ. 1994;308:295–298
  94. Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol. 2003;189:139–147
  95. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74:14–22
  96. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29:297–301
  97. Hay PE, Morgan DJ, Ison CA, et al. A longitudinal study of bacterial vaginosis during pregnancy. BJOG. 1994;101:1048–1053
  98. Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ. 2004;329:371
  99. Lamont RF, Duncan SL, Mandal D, Bassett P. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol. 2003;101:516–522
  100. Guaschino S, Ricci E, Franchi M, et al. Treatment of asymptomatic bacterial vaginosis to prevent pre-term delivery: a randomised trial. Eur J Obstet Gynecol Reprod Biol. 2003;110:149–152
  101. Kekki M, Kurki T, Pelkonen J, Kurkinen-Raty M, Cacciatore B, Paavonen J. Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial. Obstet Gynecol. 2001;97:643–648
  102. Kurkinen-Raty M, Vuopala S, Koskela M, et al. A randomised controlled trial of vaginal clindamycin for early pregnancy bacterial vaginosis. BJOG. 2000;107:1427–1432
  103. Rosenstein IJ, Morgan DJ, Lamont RF, et al. Effect of intravaginal clindamycin cream on pregnancy outcome and on abnormal vaginal microbial flora of pregnant women. Infect Dis Obstet Gynecol. 2000;8:158–165
  104. Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial. BJOG. 1999;106:652–657
  105. McGregor JA, French JI, Jones W, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol. 1994;170:1048–1060
  106. Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet. 2003;361:983–988
  107. McDonald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2007;CD000262
  108. Koumans EH, Lane SD, Aubry R, DeMott K, Berman S, Webster NJ. Evaluation of the BV component of Syracuse's Healthy Start Project. Abstract presented at MCH Epidemiology Conference at Centers for Disease Control and Prevention. Atlanta, GA, Dec. 6, 2006.
  109. McGregor JA, French JI, Parker R, et al. Prevention of premature birth by screening and treatment for common genital tract infections: results of a prospective controlled evaluation. Am J Obstet Gynecol. 1995;173:157–167
  110. Joesoef MR, Hillier SL, Wiknjosastro G, et al. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. Am J Obstet Gynecol. 1995;173:1527–1531
  111. United States Preventive Services Task Force. Screening for Bacterial vaginosis in pregnancy: recommendations and rationale. Internet Journal of Gynecology and Obstetrics. 2002;1;Available at: http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijgo/vol1n2/vaginosis.xml. Accessed March 1, 2008
  112. American College of Obstetricians and Gynecologists. Practice bulletin no.: 31: assessment of risk factors for preterm birth: clinical management guidelines for obstetrician-gynecologists. Washington, DC: The College; 2001;
  113. Hauth JC, Goldenberg RL, Andrews WW, DuBard MB, Copper RL. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med. 1995;333:1732–1736
  114. Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol. 1994;171:345–349
  115. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis: National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 2000;342:534–540
  116. Larsson PG, Bergstrom M, Forsum U, Jacobsson B, Strand A, Wolner-Hanssen P. Bacterial vaginosis: transmission, role in genital tract infection and pregnancy outcome: an enigma. APMIS. 2005;113:233–245
  117. Centers for Disease Control and Prevention. Group B strep prevention: general public: frequently asked questions. http://www.cdc.gov/groupBstrep/general/gen_public_faq.htmAccessed March 24, 2008
  118. Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs) report emerging infections program network group B streptococcus, 2006. http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs06.pdfAccessed March 24, 2008
  119. Prevention of perinatal group B streptococcal disease. MMWR Recomm Rep. 2002;51:1–28
  120. Regan JA, Klebanoff MA, Nugent RP, et al. Colonization with group B streptococci in pregnancy and adverse outcome: VIP Study group. Am J Obstet Gynecol. 1996;174:1354–1360

 The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

 Conflict of Interest: Dean V. Coonrod, MD, MPH, is a Grant Recipient from the March of Dimes Arizona Chapter to develop an internatal Care Clinic. He has funding from CMS (#1HOCMS030207 101) working on compliance with the 6 week postpartum visit as a strategy to improve preconception care and funding from Cellestis Inc (Valencia, CA) to study Quantiferon Gold in pregnancy. Brian W. Jack, MD; Phillip G. Stubblefield, MD; Lisa M. Hollier, MD, MPH; Kim A. Boggess, MD; Robert Cefalo, MD, PhD; Shanna N. Cox, MSPH; Anne L. Dunlop, MD, MPH; Kam D. Hunter, MD, PhD; Michael C. Lu, MD, MS, MPH; Jeanne A. Conry, MD, PhD; Ronald S. Gibbs, MD; and Vijaya K. Hogan, DrPH have no conflict of interest including grants, honoraria, advisory board membership, or share holdings. Mona R. Prasad, DO, MPH is the recipient of a $25,000 service grant from the March of Dimes for the year 2008.

PII: S0002-9378(08)01031-4

doi: 10.1016/j.ajog.2008.08.062

American Journal of Obstetrics & Gynecology
Volume 199, Issue 6, Supplement B , Pages S296-S309 , December 2008

Article Tools